| Gene symbol | ERBB2 | Synonyms | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | erb-b2 receptor tyrosine kinase 2 | ||||
| GTO ID | GTC2520 |
| Trial ID | NCT04650451 |
| Disease | HER2-Receptor Positive Breast Cancer |
| Altered gene | HER2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BPX-603 |
| Phase | Phase1 |
| Recruitment status | Suspended |
| Title | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors |
| Year | 2020 |
| Country | United States |
| Company sponsor | Bellicum Pharmaceuticals |
| Other ID(s) | BPX603-201A |
| Cohort 1 | |||||||||
|
|||||||||